Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort

PURPOSE: Alterations to mismatch repair (MMR) pathways are a known cause of cancer, particularly colorectal and endometrial carcinomas. Recently, checkpoint inhibitors have been approved for use in MMR-deficient cancers of any type (Prasad et al. in JAMA Oncol 4:157–158, 2018). Functional studies in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Angela S., Leung, Samuel C. Y., Gao, Dongxia, Burugu, Samantha, Anurag, Meenakshi, Ellis, Matthew J., Nielsen, Torsten O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985067/
https://www.ncbi.nlm.nih.gov/pubmed/31522348
http://dx.doi.org/10.1007/s10549-019-05438-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985067/
https://www.ncbi.nlm.nih.gov/pubmed/31522348
http://dx.doi.org/10.1007/s10549-019-05438-y

Ejemplares similares